Literature DB >> 20377426

IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines.

Kaustuv Banerjee1, P J Klasse, Rogier W Sanders, Florencia Pereyra, Elizabeth Michael, Min Lu, Bruce D Walker, John P Moore.   

Abstract

We have studied IgG subclass responses to the HIV-1 proteins gp120, gp41, p24, and Tat in individuals who control their infection without using antiretroviral drugs (HIV-1 controllers; HC) or who progress to disease (chronic progressors; CP). We also measured IgG subclass titers to gp120 in vaccinated individuals. In all cases, the IgG1 subclass dominated the overall response to each antigen. The only IgG titer that differed significantly between the HC and CP groups was to the p24 Gag protein, which was higher in the HC group. IgG1 titers to both p24 and gp120 were significantly higher in the HC group, and IgG3 anti-gp120 antibodies, although rare, were detected more frequently in that group than in CP. Overall, significantly more patients had IgG2 antibodies to gp120 than to gp41. Antibodies to other IgG subclasses were infrequent and their frequency or titers did not differ between the two patient groups. Anti-gp41 and anti-Tat responses also did not correlate with immune control, and anti-Tat antibodies were infrequently detected. Although we found isotypic differences in IgG responses to HIV-1 antigens among vaccinees and the HC and CP individuals, there were no indications of differential T(H)1:T(H)2 polarization between the different groups.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20377426      PMCID: PMC2864049          DOI: 10.1089/aid.2009.0223

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  71 in total

1.  Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy.

Authors:  Justin R Bailey; Kara G Lassen; Hung-Chih Yang; Thomas C Quinn; Stuart C Ray; Joel N Blankson; Robert F Siliciano
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

2.  Regulation of human IgG subclass production by cytokines. IFN-gamma and IL-6 act antagonistically in the induction of human IgG1 but additively in the induction of IgG2.

Authors:  Y Kawano; T Noma; J Yata
Journal:  J Immunol       Date:  1994-12-01       Impact factor: 5.422

3.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

Authors:  Punnee Pitisuttithum; Peter Gilbert; Marc Gurwith; William Heyward; Michael Martin; Fritz van Griensven; Dale Hu; Jordan W Tappero; Kachit Choopanya
Journal:  J Infect Dis       Date:  2006-11-03       Impact factor: 5.226

Review 4.  Immunoglobulin G4: an odd antibody.

Authors:  R C Aalberse; S O Stapel; J Schuurman; T Rispens
Journal:  Clin Exp Allergy       Date:  2009-02-13       Impact factor: 5.018

5.  Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia.

Authors:  Georgia D Tomaras; Nicole L Yates; Pinghuang Liu; Li Qin; Genevieve G Fouda; Leslie L Chavez; Allan C Decamp; Robert J Parks; Vicki C Ashley; Judith T Lucas; Myron Cohen; Joseph Eron; Charles B Hicks; Hua-Xin Liao; Steven G Self; Gary Landucci; Donald N Forthal; Kent J Weinhold; Brandon F Keele; Beatrice H Hahn; Michael L Greenberg; Lynn Morris; Salim S Abdool Karim; William A Blattner; David C Montefiori; George M Shaw; Alan S Perelson; Barton F Haynes
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

Review 6.  Elite control of HIV infection: implications for vaccine design.

Authors:  B M Baker; B L Block; A C Rothchild; B D Walker
Journal:  Expert Opin Biol Ther       Date:  2009-01       Impact factor: 4.388

7.  Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers.

Authors:  Olivier Lambotte; Guido Ferrari; Christiane Moog; Nicole L Yates; Hua-Xin Liao; Robert J Parks; Charles B Hicks; Kouros Owzar; Georgia D Tomaras; David C Montefiori; Barton F Haynes; Jean-François Delfraissy
Journal:  AIDS       Date:  2009-05-15       Impact factor: 4.177

8.  Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo.

Authors:  Kaustuv Banerjee; Sofija Andjelic; Per Johan Klasse; Yun Kang; Rogier W Sanders; Elizabeth Michael; Robert J Durso; Thomas J Ketas; William C Olson; John P Moore
Journal:  Virology       Date:  2009-05-02       Impact factor: 3.616

9.  CD8+ T-cell responses to different HIV proteins have discordant associations with viral load.

Authors:  Photini Kiepiela; Kholiswa Ngumbela; Christina Thobakgale; Dhanwanthie Ramduth; Isobella Honeyborne; Eshia Moodley; Shabashini Reddy; Chantal de Pierres; Zenele Mncube; Nompumelelo Mkhwanazi; Karen Bishop; Mary van der Stok; Kriebashnie Nair; Nasreen Khan; Hayley Crawford; Rebecca Payne; Alasdair Leslie; Julia Prado; Andrew Prendergast; John Frater; Noel McCarthy; Christian Brander; Gerald H Learn; David Nickle; Christine Rousseau; Hoosen Coovadia; James I Mullins; David Heckerman; Bruce D Walker; Philip Goulder
Journal:  Nat Med       Date:  2006-12-17       Impact factor: 53.440

10.  HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits.

Authors:  Weifeng Xu; Paul A Santini; John S Sullivan; Bing He; Meimei Shan; Susan C Ball; Wayne B Dyer; Thomas J Ketas; Amy Chadburn; Leona Cohen-Gould; Daniel M Knowles; April Chiu; Rogier W Sanders; Kang Chen; Andrea Cerutti
Journal:  Nat Immunol       Date:  2009-08-02       Impact factor: 25.606

View more
  62 in total

Review 1.  Strategies for eliciting HIV-1 inhibitory antibodies.

Authors:  Georgia D Tomaras; Barton F Haynes
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

2.  HIV-1 gp140 epitope recognition is influenced by immunoglobulin DH gene segment sequence.

Authors:  Yuge Wang; Pratibha Kapoor; Robert Parks; Aaron Silva-Sanchez; S Munir Alam; Laurent Verkoczy; Hua-Xin Liao; Yingxin Zhuang; Peter Burrows; Michael Levinson; Ada Elgavish; Xiangqin Cui; Barton F Haynes; Harry Schroeder
Journal:  Immunogenetics       Date:  2015-12-19       Impact factor: 2.846

3.  Divergent antibody subclass and specificity profiles but not protective HLA-B alleles are associated with variable antibody effector function among HIV-1 controllers.

Authors:  Jennifer I Lai; Anna F Licht; Anne-Sophie Dugast; Todd Suscovich; Ickwon Choi; Chris Bailey-Kellogg; Galit Alter; Margaret E Ackerman
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

4.  Viral control in chronic HIV-1 subtype C infection is associated with enrichment of p24 IgG1 with Fc effector activity.

Authors:  Amy W Chung; Jenniffer M Mabuka; Bongiwe Ndlovu; Anna Licht; Hannah Robinson; Yathisha Ramlakhan; Musie Ghebremichael; Tarylee Reddy; Philip J R Goulder; Bruce D Walker; Thumbi Ndung'u; Galit Alter
Journal:  AIDS       Date:  2018-06-19       Impact factor: 4.177

Review 5.  How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?

Authors:  Per Johan Klasse; Rogier W Sanders; Andrea Cerutti; John P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-20       Impact factor: 2.205

Review 6.  T-bet-expressing B cells during HIV and HCV infections.

Authors:  James J Knox; David E Kaplan; Michael R Betts
Journal:  Cell Immunol       Date:  2017-07-11       Impact factor: 4.868

7.  What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?

Authors:  Marina R Alexander; Rajesh Ringe; Rogier W Sanders; James E Voss; John P Moore; Per Johan Klasse
Journal:  J Virol       Date:  2015-03-25       Impact factor: 5.103

8.  Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.

Authors:  Zelda Euler; Galit Alter
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

9.  T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response.

Authors:  James J Knox; Marcus Buggert; Lela Kardava; Kelly E Seaton; Michael A Eller; David H Canaday; Merlin L Robb; Mario A Ostrowski; Steven G Deeks; Mark K Slifka; Georgia D Tomaras; Susan Moir; M Anthony Moody; Michael R Betts
Journal:  JCI Insight       Date:  2017-04-20

10.  Viremic HIV Controllers Exhibit High Plasmacytoid Dendritic Cell-Reactive Opsonophagocytic IgG Antibody Responses against HIV-1 p24 Associated with Greater Antibody Isotype Diversification.

Authors:  M Christian Tjiam; James P A Taylor; Mazmah A Morshidi; Lucy Sariputra; Sally Burrows; Jeffrey N Martin; Steven G Deeks; Dino B A Tan; Silvia Lee; Sonia Fernandez; Martyn A French
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.